STARTUPS – BioHealthOnlab BioHealth Startups

With the mission of “Cultivating Connections”, AGRI SMILE is working to solve the problem of the lack of accumulated information on cultivation in the agricultural field. In order to provide an environment in which unique cultivation methods can be established in various parts of Japan, we provide support to JA  and other production organizations to systematize cultivation techniques using software, AR/VR, etc., with the aim of introducing these techniques to JA across the country. In addition,  we have started joint research and development with companies and soil analysis. (AGRI SMILE)

Batch 2

We have developed and provided medical AR-VR services from the perspective of psychosomatic internal medicine.  The “BiPSEE Medical XR” has already been implemented in pediatric settings to reduce children’s anxiety and pain. We are developing digital therapeutics (cognitive-behavioral therapy x VR) in the mental field and are preparing for a feasibility study with collaborating medical institutions.  Our digital therapies are also being rolled out to companies as a way of preventing depression. In response to requests from corporate clients, we are also proposing a digital framework, including social VR scheme, to care for the mental health of employees who work from home. (BiPSEE, Inc.)

Batch 2

bitBiome Inc. is a technology driven start-up company based in Japan, founded in 2018. With the single-cell genomics technology specific to microorganisms (bit-MAP®), we provide the world’s only analytics service to identify exact microbial genome sequences and functions in the single-cell level resolution. Providing this technology as a next-generation microbiome analysis service, we will build the foundation to continuously generate novel scientific findings, explosively accumulate those intelligence, and expansively apply into medical and industrial resources to achieve better world. We are actively looking for business/research collaborations in broad area such as gut microbiome related to various human diseases, soil/plant bacteria related to agriculture, skin bacteria related to cosmetics, quality assurance for live bacterial therapeutics, food and so on. (bitBiome, Inc.)

Batch 2

We are developing the world’s first wearable devices which can measure changes of core body temperature in belly button and  physical condition control system with resercher in Waseda university. Now,we are maiking the personalized heatstroke prevent system and we plan to reserch of sleep with core body temperature. We predict individual physical condition change  help peoples who has never been saved with this devices and data. (MEDITA INC.)

Batch 2

PLIMES Inc. is a university spin-off company launched in April 2018 to create a pathway to market for academic research innovations originating from the research achievements at the [Artificial Intelligence Laboratory](http://www.ai.iit.tsukuba.ac.jp/) , [Center for Cybernics Research](http://www.ccr.tsukuba.ac.jp/) and Center for Innovative Medicine and Engineering at the University of Tsukuba. We are social enablers, and as a social problem-solving business, we operate to dramatically enhance user experience and social interaction for people with special needs. (PLIMES Inc.)

Batch 2

xFOREST Therapeutics aims to create a paradigm shift in drug discovery with its unique technological assets "FOREST", setting RNA structures as drug discovery targets.FOREST are technology platforms that integrate massively parallel biochemical analysis systems of up to 1 million species of RNA structures and in silico analysis pipelines. These comprehensive analyses include various RNA structures, regardless of organ, species, or virus. As a result, the technologies have enabled the search for highly specific RNA- binders. Furthermore, we will design new drugs using computational analysis of big data obtained by FOREST. (xFOREST Therapeutics Co., Ltd)

Batch 2

Our product is called “Toletta®” it is a smart IoT cat litter box. This system also ideal for detecting any abnormalities in your cat’s health that may not be directly noticeable, such as Chronic Kidney Disease. Chronic Kidney Disease is an incurable disease that affects 30% of cats , it is also tone of the leading causes in cat death. Early symptoms of this disease include an increased urine volume and decreased body weight, which toletta can measure simultaneously. We can also distinguish between various cats via our camera/face recognition technology, and all of your specific cat’s information will be available on our app, which makes our product more convenient for those who lead busy lives like those in the workforce. Our technology is very unique and innovative to the pet industry because we can help provide early detection, which leads to early treatment to one’s cat, which can prolong their lives so that everyone can live a happy cat life. (Toletta Cats Inc.)

Batch 2

ERISA was established in Matsue City, Shimane Prefecture in April 2017 as a subsidiary of a regional think tank with over 20 years of business experience. ERISA aims to commercialize a program which can predict progression to Alzheimer-type dementia from mild cognitive impairment based on MR images using AI, with the goal of solving the social problem of dementia in Shimane, an aging advanced prefecture in Japan.

Batch 1

Domolens is developing and researching the world’s first VR product to improve stuttering, an unknown language disorder with 1.2 million people in Japan and 76 million people in the world. People with stuttering improve their symptoms by experiencing social scenes that they are not good at in VR space over and over again.

Batch 1

Mealthy provides SaaS for dietary habits improvement support to prevent lifestyle-related diseases. Currently, Mealthy’s service is used in health insurance associations and supporting insured people to continue their healthcare program of specific health guidance and prevention of diabetic nephropathy. Mealthy is promoting the automation of nutritionist operations while maintaining high-quality nutrition guidance at the medical level. Mealthy’s service has already used at health insurance associations and achieved the industry’s top level cost-effectiveness.

Batch 1

United Immunity aims to cure cancer by overcoming “Cold tumor” through the practical application of T cell activation technology “T-ignite”, which was born from medical-engineering collaboration research between Mie University and Kyoto University. Cold tumor is an immunologically inactive cancer that immune checkpoint inhibitors are difficult to work on, which account for the majority of malignant tumors. Thus, there is a global need for understanding the causes and solutions of Cold tumor.

Batch 1